Answers are grounded in this paper and cite their sources.
Introduction. Nitric oxide plays a key role in the development of inflammation. In this regard, it is promising to create a drug that reduces the production of nitric oxide in the focus of inflammation. Aim. To study experimentally the anti-inflammatory and analgesic effects of an inducible nitric oxide synthase inhibitor of an aminoguanidine derivative (LIS-M). Materials and methods. The compound LIS-M in 1% aqueous solution of polyvinylpyrrolidone was administered intramuscularly at doses of 5, 10 and 20 mg/kg to 150 male Sprague Dawley rats and 50 male CD-1 mice with experimental models of inflammation and pain. The animals of the comparison group received diclofenac at a dose of 10 mg/kg, the animals of the control group received 1% aqueous solution of polyvinylpyrrolidone in an equivalent volume. The effect of the LIS-M compound on the course of experimental pathology and its analgesic potential ulcerogenic effect were evaluated. Results. In male Sprague Dawley rats, the LIS-M compound reduces acute exudative inflammation caused by injection of carrageenan, histamine or serotonin in plantar aponeurosis, inhibits the proliferation of granulation tissue and exudation around a cotton swab implanted under the skin, does not have an ulcerogenic effect. In male CD-1 mice, it weakens the pain reaction and increases the time before it occurs. Conclusion. The LIS-M compound at doses ranging from of 5 to 20 mg/kg has a pronounced antiexudative, antiproliferative and analgesic effect, not inferior to the action of diclofenac at a dose of 10 mg/kg, and does not have an ulcerogenic effect.
No takes yet. Share an insight, caveat, or question.
Vengerovskii et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: